Led by AveXis vets, Taysha adds dry powder ahead of first clinical trials for CNS gene therapy pipeline

Less than four months after launching with $30 million, Taysha has closed a $95 million series B to advance its lead CNS gene therapy programs into the clinic and build a commercially scalable GMP manufacturing facility.

Led by Fidelity Management & Research Co., the round included 11 new backers, many of which are crossover investors (see “Series B Investors”)...